IL17A and breast cancer: Out of 122 patients with breast cancer, 64 (52%) had ER-positive tumors; about 20% of ER-positive tumors contained IL-17Ahigh and/or PDL-1high cells, indicating that high expression of IL-17A and PDL1 may not be related to ER status.